Related Experiment Videos

Modulation of antifolate cytotoxicity by metabolites from dying cells in a lymphocyte clonal assay

J M Hughes1, A deFazio, M H Tattersall

  • 1Department of Cancer Medicine, University of Sydney, NSW, Australia.

Insights

Developing a methotrexate resistance assay for lymphocytes is complicated. Metabolites from dying cells can protect lymphocytes from methotrexate, interfering with accurate sensitivity testing.

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Lymphocyte clonal assays are used to study somatic cell mutations.
  • Methotrexate (MTX) is an antifolate drug used in cancer therapy.
  • Studying cellular sensitivity to antifolates requires controlled culture conditions.

Purpose of the Study:

  • To modify a lymphocyte clonal assay for studying methotrexate resistance.
  • To investigate the cytotoxicity of methotrexate under different cell densities and culture conditions.

Main Methods:

  • A lymphocyte clonal assay was adapted to study methotrexate resistance.
  • High-performance liquid chromatography (HPLC) was used to analyze culture supernatants.
  • Lymphocytes were cultured under nucleoside-free conditions at varying cell densities.

Main Results:

  • Methotrexate was not lethal to lymphocytes at densities >10^2 cells/well, even in nucleoside-free media.
  • HPLC analysis revealed hypoxanthine and thymidine release from dying cells.
  • At densities ≤10^2 cells/well, methotrexate was cytotoxic, but protected by hypoxanthine and thymidine.

Conclusions:

  • Metabolites released from dying cells can interfere with methotrexate cytotoxicity.
  • Nucleoside-free conditions alone do not prevent confounding factors in antifolate sensitivity assays.
  • The presence of metabolites complicates the development of reliable lymphocyte-based clonogenic assays for antifolate sensitivity.

Related Concept Videos